{"id":334729,"date":"2017-03-02T07:30:44","date_gmt":"2017-03-01T23:30:44","guid":{"rendered":"http:\/\/techcrunch.com\/?p=1459295"},"modified":"2017-03-02T07:30:44","modified_gmt":"2017-03-01T23:30:44","slug":"how-synthegos-founders-went-from-a-mission-to-mars-to-a-mission-to-cure-disease","status":"publish","type":"post","link":"https:\/\/people.utm.my\/asmawisham\/how-synthegos-founders-went-from-a-mission-to-mars-to-a-mission-to-cure-disease\/","title":{"rendered":"How Synthego\u2019s founders went from a mission to Mars to a mission to cure disease"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/11\/wtf-is-crispr-main.png?w=738\" class=\"\"\/><\/p>\n<div class=\"byline contributor-byline\" readability=\"8.1914893617021\">\n<div class=\"name\" readability=\"7\">\n<p><span class=\"name-container\">Alice Lloyd George<\/span> <span>Crunch Network Contributor<\/span><\/p>\n<\/p><\/div>\n<p class=\"bio\"><a href=\"http:\/\/www.rre.com\/alice-lloyd-george\/\">Alice Lloyd George<\/a> is an investor at <a href=\"http:\/\/www.rre.com\/\">RRE Ventures<\/a> and the host of <a href=\"http:\/\/theflux.libsyn.com\/podcast\">Flux<\/a>, a series of podcast conversations with leaders in frontier technology.<\/p>\n<\/div>\n<p>When an entrepreneur quits their job to found a company, you\u2019re bound to hear the words \u201cI want to build something meaningful. I want to have a bigger impact.\u201d Well, if your job is building rockets for Elon at SpaceX, what do you say? What\u2019s bigger than colonizing Mars?<\/p>\n<p>For the SpaceX engineers behind Synthego, the answer was helping cure all human disease. In an interview for Flux, I sat down with one half of the sibling duo, co-founder and CEO Paul Dabrowski, to learn about scaling a platform of tools for scientists.<\/p>\n<p>Paul revealed why CRISPR is so much more precise than other gene-editing techniques, the huge impact it will have on the AgBio industry, how China\u2019s been pushing ethical boundaries and his thoughts on IP and licensing. He also discussed what it\u2019s like building a company with your brother, why he\u2019s excited that Silicon Valley is pursuing big innovations again and how his time at SpaceX has shaped the way he thinks.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">PD: The interesting thing we saw [at SpaceX] was how these two concepts of rapid iteration and automation really got applied for making hardware. We realized the training and the skill set we got wasn\u2019t just for computers. It was really a philosophy and a way of thinking. At SpaceX we were quite inspired, it\u2019s quite a big vision, looking to colonize other planets. After a couple of years there we decided, hey let\u2019s strike out on our own, start a couple of our own companies. At that point in time the iPhone app space was taking off and we were on the front edge of that and managed to make an automation system for creating iPhone apps. We decided, hey let\u2019s look around and see what other big impact things we can work on.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">That led us to looking into biology and biotech. We recognized pretty quickly that a lot of the processes were very difficult to do in the sciences. Meaning, it\u2019s really hard to get consistent results. It\u2019s hard to scale it up. Some of the core concepts we saw as computer engineers, those weren\u2019t necessarily being applied in the field. We saw this opportunity to make a platform for doing science. It was clear that there was an opportunity to help science go faster and that the potential rewards and the value of what we could contribute there is much bigger than anywhere else. I don\u2019t know where else you could focus and have such a big impact.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">AMLG<\/strong><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">: So you\u2019re basically democratizing access for scientists, right? What kind of tools do you provide for them in the lab?<\/strong><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">PD: Right now we\u2019re focused on a kit that enables people to do CRISPR genome engineering. They tell us the target they\u2019re trying to modify and we ship them this kit and it all comes prepared. Previously, you might have to spend many weeks to months waiting for this kit to be produced, or you\u2019d have to make it yourself in the lab and spend evenings and potentially a couple of weeks of work.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">Now we ship it to you within days and it only costs a few hundred dollars versus in the thousands. And the quality is stellar. We\u2019re able to get editing rates that are 80-90+ percent. For reference, that means if you\u2019re trying to modify cells, you\u2019ve got a pool of cells, and some fraction of those get modified correctly. With CRISPR, typically you might expect 10, 20, 30, 40 percent. With our product, we\u2019ve almost doubled that. Our goal would be to make it 100 percent. Because it\u2019s actually a lot of effort to find the cells that have been modified correctly. Imagine if you\u2019re trying to save your word-processor file and only 60 percent of the characters you typed were actually saved correctly. I\u2019d be a bit of a disaster.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-1359851 size-large\" src=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-450853983.jpg?w=680&#038;h=453\" alt=\"DNA molecules\" width=\"680\" height=\"453\" srcset=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-450853983.jpg?w=680&#038;h=453 680w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-450853983.jpg?w=1360&#038;h=906 1360w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-450853983.jpg?w=150&#038;h=100 150w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-450853983.jpg?w=300&#038;h=200 300w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-450853983.jpg?w=768&#038;h=512 768w\" sizes=\"(max-width: 680px) 100vw, 680px\"\/><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">AMLG:<\/strong> <strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">Interesting. From my understanding, one of the drawbacks of CRISPR has been these unintended effects, where the wrong piece of DNA gets edited. How are you able to get such high accuracy rates?<\/strong><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">PD: What you\u2019re describing is off-target effects. Usually you\u2019ve got a target you\u2019re trying to modify and then sometimes you modify the wrong thing. The technique we\u2019re using, specifically synthetic RNA, actually decreases that an order of magnitude. Then the informatics of choosing which target can also decrease that drastically. The quality of the synthetic RNA itself is the third factor. If you have all three of those, your off-target rates can be extremely low. As in, you can pick cells and there\u2019s absolutely no off-target effects and it can become a very precise tool.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">AMLG: So the scientists and labs that use your kit, what are they using it for so far, what are they modifying?<\/strong><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">PD: We\u2019ve heard of all sorts of organisms being used. That\u2019s actually the magical power of CRISPR \u2014 it works in most any type of cell. So in plants, in animals, we\u2019ve even heard of jellyfish. We recently did a grant application \u2014 we\u2019re going to be giving away $100,000 of our product and we had a wide range of applications. It demonstrated that it can be used in pretty much any organism \u2014 lettuce plants, the Tasmanian devil, the list goes on and on.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">AMLG: The Tasmanian devil?<\/strong><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">PD: There is a situation, it\u2019s a pretty tragic situation, where I believe there is a transmissible cancer that grows near the faces of Tasmanian devils. So they\u2019ve been transmitting cancer from one organism to the next and the population is at risk. There are projects to try and understand that. To save the Tasmanian devil, I guess.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">AMLG: It seems like there\u2019s an infinite range of use cases, from things like agriculture to human disease. How big do you think this industry could be\u00a0?<\/strong><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">PD: The two you just mentioned are really the starting points. In terms of the scope of what we\u2019re trying to do, yes we\u2019re definitely enabling CRISPR, but we also have a long-term plan to help researchers actually do their science. Not just sending them a kit, but actually being able to do the experiment for them in the future. If you look at the broader picture of what we\u2019re trying to achieve at Synthego, the name of the game is ultimately to create platforms and tools that scientists can use to cure all diseases.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">AMLG: Cure all diseases \u2014 you don\u2019t usually see that in any sentence of any company. We\u2019re going to just cure all human disease.<\/strong><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">PD:\u00a0<\/strong>I\u2019m not claiming we\u2019re going to do that. But we\u2019re going to be helping to create the tools that can enable the scientists to do that. Arguably it\u2019s possible in our lifetimes.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">On the therapeutic side, one really exciting specific therapeutic is in the immunotherapy space, CAR-Ts. I think a lot of people have heard of these. Immune cells are modified to go hunt down cancer let\u2019s say, and that modification can be done using CRISPR. We have collaborators in that space and there\u2019s some amazing progress. For example, in the Seattle Children\u2019s Research Hospital they recently had complete remission of leukemia in a six-year-old, who had all sorts of other drugs fail. So there\u2019s light at the end of the tunnel that certain cancers might be able to be attacked and addressed directly, rather than indirectly through small molecules or chemotherapy.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-1359850 size-large\" src=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-168832278.jpg?w=680&#038;h=510\" alt=\"DNA molecule\" width=\"680\" height=\"510\" srcset=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-168832278.jpg?w=680&#038;h=510 680w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-168832278.jpg?w=1360&#038;h=1020 1360w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-168832278.jpg?w=150&#038;h=113 150w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-168832278.jpg?w=300&#038;h=225 300w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/07\/gettyimages-168832278.jpg?w=768&#038;h=576 768w\" sizes=\"(max-width: 680px) 100vw, 680px\"\/><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">AMLG: That\u2019s incredible. Do you think it\u2019s possible that CRISPR could help start curing cancer in the next 10-20 years? In our lifetime, will there still be cancer if CRISPR goes to plan?<\/strong><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">PD: I don\u2019t know about targeting every type of cancer. One of the original flaws in the notion of curing cancer is that cancer is one thing, because any given specific case of cancer is very unique and heterogeneous, meaning there\u2019s many different types of cells that are actually gone wrong. So to say that all cancer is going to be cured may be a stretch, but I think there will definitely be certain classes that are cured in our lifetimes.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\"><strong class=\"m_6976085250356162041gmail-markup--strong m_6976085250356162041gmail-markup--p-strong\">AMLG: What about the agriculture side?\u00a0<\/strong><\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">PD: What\u2019s interesting is that CRISPR really brings down the cost of creating a new seed line or incorporating traits from a difficult-to-breed seed. So CRISPR is going to be used more like traditional plant breeding rather than the GMO sort of situation. That is going to be very powerful.<\/p>\n<p class=\"m_6976085250356162041gmail-graf m_6976085250356162041gmail-graf--p\">If the time to bring a seed to market is also much faster, we can see the seed market growing in diversity. That\u2019s a big deal, because you have a lock-up in the market, between the big AgBio companies, and there\u2019s concern on the part of the farmers, on the part of society. Then you have this overwhelming context of global warming happening and changing what weather conditions look like. So being able to tailor plants to microclimates is something that might be possible with CRISPR in the coming years.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" width=\"680\" height=\"383\" src=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/11\/wtf-is-crispr-main.png?w=680\" class=\"attachment-large size-large wp-post-image\" alt=\"wtf-is-crispr-main\" srcset=\"https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/11\/wtf-is-crispr-main.png?w=680 680w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/11\/wtf-is-crispr-main.png?w=1360 1360w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/11\/wtf-is-crispr-main.png?w=150 150w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/11\/wtf-is-crispr-main.png?w=300 300w, https:\/\/tctechcrunch2011.files.wordpress.com\/2016\/11\/wtf-is-crispr-main.png?w=768 768w\" sizes=\"(max-width: 680px) 100vw, 680px\" \/>&nbsp;When an entrepreneur quits their job to found a company, you&#8217;re bound to hear the words &#8220;I want to build something meaningful. I want to have a bigger impact.&#8221; Well, if your job is building rockets for Elon at SpaceX, what do you say? What&#8217;s bigger than colonizing Mars? For the SpaceX engineers behind Synthego, the answer was helping cure all human disease. <a href=\"https:\/\/techcrunch.com\/2017\/03\/01\/how-synthegos-founders-went-from-a-mission-to-mars-to-a-mission-to-cure-disease\/?ncid=rss\">Read More<\/a><\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=d6uXYUwgbpk:kkbO6m7fc_c:2mJPEYqXBVI\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?d=2mJPEYqXBVI\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=d6uXYUwgbpk:kkbO6m7fc_c:7Q72WNTAKBA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?d=7Q72WNTAKBA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=d6uXYUwgbpk:kkbO6m7fc_c:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=d6uXYUwgbpk:kkbO6m7fc_c:-BTjWOF_DHI\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?i=d6uXYUwgbpk:kkbO6m7fc_c:-BTjWOF_DHI\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=d6uXYUwgbpk:kkbO6m7fc_c:D7DqB2pKExk\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?i=d6uXYUwgbpk:kkbO6m7fc_c:D7DqB2pKExk\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?a=d6uXYUwgbpk:kkbO6m7fc_c:qj6IDK7rITs\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/Techcrunch?d=qj6IDK7rITs\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Techcrunch\/~4\/d6uXYUwgbpk\" height=\"1\" width=\"1\" alt=\"\"\/> <\/p>\n","protected":false},"author":5817,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[25],"tags":[59,66,26],"class_list":["post-334729","post","type-post","status-publish","format-standard","hentry","category-technology","tag-media","tag-techcrunch","tag-technology"],"_links":{"self":[{"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/posts\/334729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/users\/5817"}],"replies":[{"embeddable":true,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/comments?post=334729"}],"version-history":[{"count":0,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/posts\/334729\/revisions"}],"wp:attachment":[{"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/media?parent=334729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/categories?post=334729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/people.utm.my\/asmawisham\/wp-json\/wp\/v2\/tags?post=334729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}